ACRS - Aclaris Therapeutics GAAP EPS of -$0.41 beats by $0.05 revenue of $7.75M beats by $5.76M
- Aclaris Therapeutics press release ( NASDAQ: ACRS ): Q4 GAAP EPS of -$0.41 beats by $0.05 .
- Revenue of $7.75M (+416.7% Y/Y) beats by $5.76M .
- As of December 31, 2022, Aclaris had aggregate cash, cash equivalents and marketable securities of $229.8 million compared to $225.7 million as of December 31, 2021.
For further details see:
Aclaris Therapeutics GAAP EPS of -$0.41 beats by $0.05, revenue of $7.75M beats by $5.76M